Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Objectives: To evaluate the impact of a treatment switch to dolutegravir plus lamivudine on the soluble inflammatory biomarkers of HIV-infected patients treated in a real-life setting. Materials and methods: This was a longitudinal study that enrolled virologically-suppressed patients on stable 3-dr...

Full description

Bibliographic Details
Main Authors: Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
inflammation
inflammatory biomarkers
dual therapy
dolutegravir
lamivudine
Online Access:http://dx.doi.org/10.1080/25787489.2022.2080625

Internet

http://dx.doi.org/10.1080/25787489.2022.2080625

Similar Items